MedTrace Logo

Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer

NCT01934478 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2023-03-29

No results posted yet for this study

Summary

Based on fundamental study （in Vitro and in Vivo, Pro. Jianjian Li）， Her2 expression would be changed from negative to positive by cancer irradiation with liner-accelerator at dose 6GY or up. The propose of this study is to reveal the irradiation result on Her2 expression in human breast cancer.

Conditions

  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Sponsors & Collaborators

  • Qingdao Central Hospital

    lead OTHER

Principal Investigators

  • ketao lan, M.D. · Qingdao Health Bereau

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2022-12-30
Completion
2022-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01934478 on ClinicalTrials.gov